Literature DB >> 19968719

Frequent STAT3 activation is associated with Mcl-1 expression in nasal NK-cell lymphoma.

M Tsutsui1, H Yasuda, H Suto, H Imai, Y Isobe, M Sasaki, Y Kojima, K Oshimi, K Sugimoto.   

Abstract

Nasal natural killer (NK)-cell lymphoma was resistant to various antitumor agents. Although high expression of p-glycoprotein has been reported, other molecular mechanism of the chemo-resistance is largely unknown. Activation of STAT3 and expression of major apoptosis-related proteins Bcl-2, Bcl-x, and Mcl-1 were analyzed by immunohistochemistry. Effects of STAT3 inhibitor AG490 on NK-YS cell line were analyzed by Western blotting and flow cytometric apoptosis assay. STAT3 was activated in six of the nine nasal NK-cell lymphomas (67%). In contrast, STAT3 activation was detected in 35% of diffuse large B-cell lymphoma (DLBCL) and in 10% of follicular lymphoma (FL). Frequent activation of STAT3 was significantly correlated with Mcl-1 expression in nasal NK-cell lymphoma, i.e., Mcl-1 was positive in five of six STAT3-active cases and negative in all three STAT3-inactive ones. In DLBCL, not only six out of seven STAT3-active cases (86%) but also eight out of thirteen STAT3-inactive cases (62%) were positive for Mcl-1 expression. Latent membrane protein-1 was positive in four nasal NK-cell lymphomas, among which three cases showed intermediate STAT3 activation. Inhibition of STAT3 activation by JAK inhibitor AG490 decreased Mcl-1 expression and induced apoptosis in STAT3-active NK-YS cells. Serum starvation rather increased the Mcl-1 level in NK-YS cells, and this effect was also canceled by AG490. These results suggest that activation of STAT3-Mcl-1 axis may play a role in the chemotherapy resistance of nasal NK-cell lymphoma. The pathway may be one of the future therapeutic targets of this intractable disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19968719     DOI: 10.1111/j.1751-553X.2009.01204.x

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  14 in total

1.  STAT3 inhibition reduces toxicity of oncolytic VSV and provides a potentially synergistic combination therapy for hepatocellular carcinoma.

Authors:  S Marozin; J Altomonte; K A Muñoz-Álvarez; A Rizzani; E N De Toni; W E Thasler; R M Schmid; O Ebert
Journal:  Cancer Gene Ther       Date:  2015-05-01       Impact factor: 5.987

2.  STAT3 activation is associated with cerebrospinal fluid interleukin-10 (IL-10) in primary central nervous system diffuse large B cell lymphoma.

Authors:  Takashi Mizowaki; Takashi Sasayama; Kazuhiro Tanaka; Katsu Mizukawa; Kumi Takata; Satoshi Nakamizo; Hirotomo Tanaka; Hiroaki Nagashima; Masamitsu Nishihara; Takanori Hirose; Tomoo Itoh; Eiji Kohmura
Journal:  J Neurooncol       Date:  2015-06-17       Impact factor: 4.130

3.  Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells.

Authors:  Elina Parri; Heikki Kuusanmäki; Daria Bulanova; Satu Mustjoki; Krister Wennerberg
Journal:  Blood Adv       Date:  2021-04-13

4.  Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer.

Authors:  E P Booy; E S Henson; S B Gibson
Journal:  Oncogene       Date:  2011-01-24       Impact factor: 9.867

5.  Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling.

Authors:  Heikki Kuusanmäki; Olli Dufva; Elina Parri; Arjan J van Adrichem; Hanna Rajala; Muntasir M Majumder; Bhagwan Yadav; Alun Parsons; Wing C Chan; Krister Wennerberg; Satu Mustjoki; Caroline A Heckman
Journal:  Oncotarget       Date:  2017-10-31

6.  A neutralized human LMP1-IgG inhibits ENKTL growth by suppressing the JAK3/STAT3 signaling pathway.

Authors:  Yuan Mao; Jun Wang; Mingzhi Zhang; Weifei Fan; Qi Tang; Siping Xiong; Xiaojun Tang; Juqing Xu; Lin Wang; Shu Yang; Suyao Liu; Li Xu; Yan Chen; Lin Xu; Rong Yin; Jin Zhu
Journal:  Oncotarget       Date:  2017-02-14

7.  The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity.

Authors:  Ryan C Thompson; Iosif Vardinogiannis; Thomas D Gilmore
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

8.  Resveratrol induces cell cycle arrest and apoptosis in malignant NK cells via JAK2/STAT3 pathway inhibition.

Authors:  Ly Quoc Trung; J Luis Espinoza; Akiyoshi Takami; Shinji Nakao
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240

9.  Resveratrol prevents EBV transformation and inhibits the outgrowth of EBV-immortalized human B cells.

Authors:  J Luis Espinoza; Akiyoshi Takami; Ly Quoc Trung; Shunichi Kato; Shinji Nakao
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

10.  Inhibitory effects of resveratrol on hepatitis B virus X protein-induced hepatocellular carcinoma.

Authors:  Seungmo Park; Jihae Lim; Jong Rhan Kim; Seongbeom Cho
Journal:  J Vet Sci       Date:  2017-12-31       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.